AS/Spondyloarthritis

cancer search news magnify

No Increased Malignancy Risk with Ixekizumab

Jack Cush, MD

A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA). The observed incidences of malignant neoplasms were consistent with the US general

Read Article
Biologic experienced ankylosing spondylitis patient show better retention on TNF compared to IL-17 inhibitors. 148 AS pts (F/U 31 mos), IL-17i drug survival trended better but only signif after 3yrs. More D/C w/ higher BASDAI (HR: 1.3) & ^# prior biologics (HR 1.62) https://t.co/5HXGsV4xol
Dr. John Cush @RheumNow( View Tweet )
GLP 1 Receptor Agonists in axSpA Dr. David Liew reviews POS1232 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/88Ms7ce7XX https://t.co/tt3qZH1hJT

Links:

Dr. John Cush @RheumNow( View Tweet )
HLA-B27 Testing in Practice A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined. https://t.co/oq7GNhzwZd
Dr. John Cush @RheumNow( View Tweet )
MRI Lesions in Early axSpA vs Non-axSpA Dr. Adela Castro reports on abstract OP0310 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/sVWpyUT1IY https://t.co/wzobROoH1K

Links:

Dr. John Cush @RheumNow( View Tweet )
AI Advances axSpA Diagnosis with Multimodal MRI Dr. Bella Mehta reports on abstract OP0307 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/fpgwQniSA5 https://t.co/EbT9v821xb

Links:

Dr. John Cush @RheumNow( View Tweet )
Assessment of Peripheral Arthritis in Spondyloarthritis Dr. Antoni Chan talks with Dr. Dafne Capelusnik about abstract POS0257 presented at the 2025 EULAR meeting in Barcelona. https://t.co/E6l6qvNnox https://t.co/gLbMjF406q

Links:

Dr. John Cush @RheumNow( View Tweet )
Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal https://t.co/Sa10k6neRP
Dr. John Cush @RheumNow( View Tweet )
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” framework has https://t.co/NYgivNRgUV
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

PCR: Prevalence, Cost, & Risk (6.27.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article
lab.test.genetics.lavender.pcr

HLA-B27 Testing in Practice

Jack Cush, MD

A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined.

Read Article
back, LBP, spine, AS

Imaging in Axial Spondyloarthritis

Adela Castro, MD

The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression. As imaging technology continues to evolve, its role in axSpA management is expected to expand,

Read Article
EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes. https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6

Links:

Dr. John Cush @RheumNow( View Tweet )
SI AS SpA ACR

Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation

MedPage Today

Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.

Read Article
Expanding the IL-17 Therapeutic Landscape IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush @RheumNow( View Tweet )
Putting IL17i into ‘focus’ for SpA-associated uveitis The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU
Dr. John Cush @RheumNow( View Tweet )
Difficult to Treat Axial Spondyloarthritis Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona. https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF

Links:

Dr. John Cush @RheumNow( View Tweet )
Lessons on Uveitis and AxSpA Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm

Links:

Dr. John Cush @RheumNow( View Tweet )
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush @RheumNow( View Tweet )
smartphone

Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia

Antoni Chan, MD, PhD

The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA

Read Article
Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

Links:

Dr. John Cush @RheumNow( View Tweet )
⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l

Links:

Adela Castro @AdelaCastro222( View Tweet )
Sacroiliac joint involvement in #Psoriatic_arthritis 🔹️681 patients 🔹️Age 45 🔹️31% MRI-positive sacroiliitis 🔹️29% radiographic sacroiliitis 🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis POS0297 #EULAR2025 @RheumNow https://t.co/gKANc6mNZB

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Data from COAST-V study (post hoc) 🔹️Ixekizumab in #axSpA 🔹️Efficacy stratified by CRP level 🔹️Better treatment response in the elevated compared to the normal CRP group OP0699 #EULAR2025 @RheumNow https://t.co/1mVoly3Gws

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )

Recent Blogs

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics. Read Post

A Domain-Based Approach to the GRAPPA Psoriatic Arthritis Treatment Recommendations

Laura Coates
heel enthesitis spur calcaneal

With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.

Read Post
×